- Onset or exacerbation of pneumonia at least 72 hours after admission to an acute care
facility or onset of pneumonia in a nursing home or rehabilitation facility with
subsequent transfer to an acute care facility
- Diagnosis of hospital-acquired pneumonia requiring mechanical ventilatory support
- Patient or Patient's legal guardian must sign written informed consent for study
participation, pretreatment, and Day 7 bronchoscopy
- Patients with hospital-acquired pneumonia caused by pathogens resistant to MERREM
- Patients with allergies to cephalosporins, penicillins and carbapenems
- Patients taking anticonvulsant therapy for a known seizure disorder
- Patients with lung cancer
- Patients with cystic fibrosis, acquired immune deficiency syndrome (AIDS),
neutropenia, active tuberculosis, or patients taking immunosuppressive therapy in
preparation for or following an organ transplant.
- Patients who are pregnant or breast feeding
- Patients who are unlikely to survive
- Patients with certain infections in another area requiring treatment with additional
antibiotics
- Patients with other underlying conditions that would make it difficult to interpret
response to study drug.
- Patients who have been part of another clinical study 30 days before entry into this
study.
- Patients with hypotension (systolic BP serum bicarbonate
- Patients with profound hypoxia